Shane Barton sold $1.6M of BIOA
Principal Accounting Officer at BioAge Labs, Inc.. 62,566 shares at an average of $25.20, traded Jun 29, 2026, filed Jul 1, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.6M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001836297-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 29, 2026 | MOption exercise Common Stock10b5-1 | +9,301 | $10.85 | $101k | 11,933 | Jul 1, 2026 |
| Jun 29, 2026 | MOption exercise Common Stock10b5-1 | +7,261 | $8.39 | $61k | 19,194 | Jul 1, 2026 |
| Jun 29, 2026 | MOption exercise Common Stock10b5-1 | +8,958 | $4.30 | $39k | 28,152 | Jul 1, 2026 |
| Jun 29, 2026 | MOption exercise Common Stock10b5-1 | +14,198 | $4.38 | $62k | 42,350 | Jul 1, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stock10b5-1 | -42,350 | $25.21 | $1.1M | 0 | Jul 1, 2026 |
| Jun 30, 2026 | MOption exercise Common Stock10b5-1 | +4,290 | $10.85 | $47k | 4,290 | Jul 1, 2026 |
| Jun 30, 2026 | MOption exercise Common Stock10b5-1 | +4,000 | $8.39 | $34k | 8,290 | Jul 1, 2026 |
| Jun 30, 2026 | MOption exercise Common Stock10b5-1 | +4,065 | $4.30 | $17k | 12,355 | Jul 1, 2026 |
| Jun 30, 2026 | MOption exercise Common Stock10b5-1 | +7,861 | $4.38 | $34k | 20,216 | Jul 1, 2026 |
| Jun 30, 2026 | SOpen-market sale Common Stock10b5-1 | -20,216 | $25.19 | $509k | 0 | Jul 1, 2026 |
| Jun 29, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,301 | $0.00 | $0 | 17,589 | Jul 1, 2026 |
| Jun 29, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,261 | $0.00 | $0 | 21,016 | Jul 1, 2026 |
| Jun 29, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,958 | $0.00 | $0 | 31,042 | Jul 1, 2026 |
| Jun 29, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -14,198 | $0.00 | $0 | 75,802 | Jul 1, 2026 |
| Jun 30, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,290 | $0.00 | $0 | 13,299 | Jul 1, 2026 |
| Jun 30, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,000 | $0.00 | $0 | 17,016 | Jul 1, 2026 |
| Jun 30, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,065 | $0.00 | $0 | 26,977 | Jul 1, 2026 |
| Jun 30, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,861 | $0.00 | $0 | 67,941 | Jul 1, 2026 |
Related signals
Other insiders at BioAge Labs, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $157k 8,820 shares | -100% | |
| 11Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $151k 7,433 shares | -100% | |
| 11Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $139k 7,433 shares | -100% | |
| 40Moderate | BioAge Labs, Inc. | Dov A Goldstein Md Chief Financial Officer | $532k 27,000 shares | -55% | |
| 50Moderate | BioAge Labs, Inc. | Kristen Fortney Chief Executive Officer | $4.2M 233,107 shares | -19% | |
| 25Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $95k 7,433 shares | -100% | |
| 12Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $216k 18,000 shares | -100% | |
| 21Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $702k 68,897 shares | -100% | |
| 29Weak | BIOAbuy BioAge Labs, Inc. | Shane Barton Principal Accounting Officer | $47k 2,632 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.